fidarestat has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramana, KV; Saxena, A; Shoeb, M; Srivastava, SK; Tammali, R | 1 |
| Hotta, N; Ishii, J; Kaneko, T; Kikkawa, R; Koike, Y; Matsuoka, K; Sakamoto, N; Shigeta, Y; Sugimura, K; Takahashi, A; Toyota, T | 1 |
1 trial(s) available for fidarestat and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Electrophysiology; Enzyme Inhibitors; Female; Glycated Hemoglobin; Humans; Hypesthesia; Imidazoles; Imidazolidines; Male; Middle Aged; Pain; Paresthesia; Placebos | 2001 |
1 other study(ies) available for fidarestat and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Aldose reductase inhibition suppresses azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice.
Topics: Aldehyde Reductase; Animals; Anticarcinogenic Agents; Azoxymethane; Colon; Colonic Neoplasms; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme Inhibitors; HT29 Cells; Humans; Imidazolidines; Inflammation Mediators; Intestinal Mucosa; Male; Mice, Inbred C57BL; Obesity; Oxidative Stress; Precancerous Conditions; Signal Transduction | 2014 |